Dendritic Cell Vaccine for Prostate Cancer from United States
Dendritic cell vaccine for prostate cancer consists of autologous dendritic cells loaded with tumor-associated antigens and matured ex vivo for personalized cancer vaccination. This product is a cell therapy product under tariff item 3002.51.00, as it involves modified cell cultures for therapeutic use.
Duty Rate — United States → Canada
0%
Import Tips
• Confirm that the product is classified as a cell therapy product and not as a vaccine under heading 30.02
• Provide evidence of the ex vivo maturation and antigen loading to CBSA
• Ensure compliance with Health Canada's Biologics and Genetic Therapies Directorate